Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 17,015

Document Document Title
WO/2014/066964A1
The present Certificate of Addition relates to the use of pharmaceutical compositions containing a Mas receptor agonist, such as Angiotensin-(1-7), for treating degenerative muscular diseases.  
WO/2014/071168A3
Methods and compositions useful for reducing loss of muscle function caused by bone metastasis in a subject with cancer. In certain embodiments, the methods of the present invention include administering to a cancer patient compositions ...  
WO/2014/071131A1
The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.  
WO/2014/065413A1
 A compound represented by general formula [I] or a pharmaceutically acceptable salt thereof. (In the formula, each symbol is as defined in the description.)  
WO/2014/063602A1
Disclosed is a drug targeting delivery adjuvant, which is at least one selected from the group of pentoses selected from xylose and arabinose; hexoses selected from glucose, galactose, fructose and mannose; sugar alcohols selected from s...  
WO/2014/065341A1
The present invent addresses the problem of providing a medicine for treating amyotrophic lateral sclerosis, a disease for which there is currently no effective therapeutic agent, and provides a therapeutic agent for amyotrophic lateral ...  
WO/2014/059403A1
Described herein are chimeric proteins, pharmaceutical compositions and methods for treating organophosphate exposure and poisoning (e.g., nerve agent poisoning, pesticide poisoning) in a subject (e.g., a human subject) and preventing or...  
WO/2014/059013A1
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e...  
WO/2014/058000A1
The purpose of the present invention is to provide a 5-HT2B receptor antagonist which does not induce problematic adverse side effects or the like and can be used safely. Provided are a serotonin 2B receptor antagonist and a prophylactic...  
WO/2014/054635A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/055905A1
Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate ("EGCg") in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, th...  
WO/2014/054634A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/053857A1
Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. Th...  
WO/2014/050779A1
To provide a combination therapy for cancer, which comprises a combination of a GSK3 inhibitor and an anti-DR5 antibody. Provided are a pharmaceutical product and a combination therapy, each of which comprises a combination of various an...  
WO/2014/051398A1
The present invention relates to a composition for promoting differentiation of myoblast, comprising Acecainide or Procainamide which is a derivative of Acecainide, or pharmaceutically acceptable salts of Acecainide, to a method for prom...  
WO/2014/049841A1
The objective of the present invention is to provide a new medicinal use of clarithromycin. The present invention is a therapeutic agent or a preventive agent for meibomian gland dysfunction or meibomian gland blockage and comprises clar...  
WO/2014/048071A1
The present invention relates to a pharmaceutical composition of PRCP antagonist, PREP antagonist, or PRCP-PREP dual antagonist. The present invention also relates to a pharmaceutical composition jointly using PRCP antagonist and mTOR an...  
WO/2014/046065A1
Provided is a material that, as a myocardial/cardiovascular regeneration device, is for the treatment of advanced heart failure, and with respect to the fundamental treatment of intractable circulatory diseases regarding which not only s...  
WO/2014/047497A1
Disclosed are nutritional compositions, and methods of using and making the nutritional compositions, that include calcium beta-hydroxy-beta-methylbutyrate and protein. The calcium beta-hydroxy-beta-methylbutyrate is in sequestered or io...  
WO/2014/043696A3
The invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis. In particular, the invention relates to pharmaceutical compositions, kits, methods, and uses for the treatm...  
WO/2014/038623A1
Provided is a therapeutic agent for diseases associated with central nervous system (CNS) and/or peripheral nervous system (PNS) cholinergicity, diseases associated with smooth muscle contraction, endocrine diseases, diseases associated ...  
WO/2014/039916A1
Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Gi...  
WO/2014/039920A1
Methods and kits for treating or reducing the likelihood of neurotoxin-induced respiratory failure in a subject, such as a victim of neurotoxic envenomation are provided. Also provided are methods for treating or reducing the likelihood ...  
WO/2014/040077A1
Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a s...  
WO/2014/033654A1
The present invention provides a compound of formula (I) in acetate salt form (I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacological...  
WO/2014/034756A1
The present invention relates to the provision of a pharmaceutical composition for use in the treatment of status epilepticus or a method for treating status epilepticus. The present invention provides a pharmaceutical composition for us...  
WO/2014/030624A1
Disclosed are: a therapeutic agent for myotonic dystrophy, particularly myotonic dystrophy associated with impaired glucose tolerance or diabetes; and a therapeutic agent for impaired glucose tolerance or diabetes each associated with my...  
WO/2014/030514A1
The present invention addresses the problem of providing a muscle atrophy inhibitor that is efficacious for disuse muscle atrophy and age-related muscle atrophy and easy to use. The muscle atrophy inhibitor comprises, as an active ingred...  
WO/2014/026330A1
The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.  
WO/2014/028025A1
Disclosed is a compound for treatment of Myotonic Dystrophy type 1 having the formula (I) wherein X is selected from the group consisting of O, N, C, or S, Y is a homo- or heteroatomic 5-membered ring comprising one or more atoms selecte...  
WO/2014/028459A1
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...  
WO/2014/026372A1
Disclosed is a pharmaceutical composition for inhibiting autophagy of motor neurons containing an effective amount of an active ingredient. The active ingredient is selected from the following groups: a compound of formula (I), pharmaceu...  
WO/2014/026140A1
Disclosed herein are methods for diagnosing, prognosing and treating muscular dystrophy. Also disclosed are methods of determining the effectiveness of an agent for the treatment of muscular dystrophy. Provided are methods of enhancing m...  
WO/2014/024984A1
The purpose of the present invention is to provide a hydrogen mixed gas supply device capable of administering a mixed gas having the hydrogen gas concentration and the oxygen gas concentration thereof each appropriately adjusted in acco...  
WO/2014/023007A1
Provided is a synthetic peptide derived from PEDF, which has 20-39 amino acid residues. Also provided are pharmaceutical compositions containing the synthetic peptide and the use thereof. The peptide is useful in promoting muscle or tend...  
WO/2014/019855A1
The present invention concerns a method for preparing a creatine fatty ester or derivative thereof comprising at least one step consisting in reacting a diprotected creatinine with a molecule bearing at least one alcohol functional group...  
WO/2014/016417A1
The present invention relates to HMGB1 variants that maintain HMGB1 wild type chemoattractant function while displaying abolished cytokine and/or chemokine stimulating properties. Such molecules are useful in therapy.  
WO/2014/016837A1
Compositions and methods utilizing thiol-containing short peptides having the sequence Cys-Lys-Met-Cys (SEQ ID NO: 1) and optionally N- and C- terminal modifications are provided, for increasing carnitine level in muscle tissues, and tre...  
WO/2014/015523A1
The invention relates to novel heteroaryl and heterocycle compounds and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3k and for treating inflammatory and autoimmune disorders dise...  
WO/2014/009738A3
The invention provides a compound capable of inhibiting ubiquitination for use in treating a disorder or symptom associated with reduced dystroglycan function in a subject.  
WO/2014/012050A3
Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.  
WO/2014/007620A3
The invention relates to an oligonucleotide and to a pharmaceutical composition comprising said oligonucleotide. This oligonucleotide is able to bind to a region of a first exon from a dystrophin pre-mRNA and to a region of a second exon...  
WO/2014/004647A1
Nutritional products, compositions, functional ingredients, medical foods, pharmaceutical preparations and methods of use are disclosed for support and improvement of athletic performance (strength, flexibility, endurance, balance, and c...  
WO/2014/004470A1
Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).  
WO/2014/003154A1
An NO production-enhancing agent, which comprises citrulline or a salt thereof and serine or a salt thereof as active ingredients; an agent for preventing the deterioration in a vascular endothelial function or improving the vascular end...  
WO/2014/001314A1
The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE 10). In particular, the invention relates to combinations of 1-aryl-4- methyl-[1,2,4]triazolo[4,3-a]-quin...  
WO/2014/000032A1
The present invention relates to phenyl amino pyrimidine bicyclic compounds formula (I) which are inhibitors of protein kinases including JAK kinases. In particular the compounds are active against JAK1, JAK2, JAK3 and TYK2 kinases. The ...  
WO/2013/189241A1
A pyrimidine diamine derivative as represented by formula (I), pharmaceutical salts thereof, pharmaceutical compositions containing the derivative, a preparation method therefor, and pharmaceutical uses thereof. The compound and the phar...  
WO/2013/187727A1
The present invention relates to novel phenylalkyl sulfamate compounds, a method for preventing or treating a disease associated with muscle spasm. The present invention ensures the enhancement of muscle relaxation activity essential for...  
WO/2013/183747A1
Provided is a material which can convert a skeleton muscle into a slow-fiber-type one and can improve or recover muscle mass or endurance. An agent for converting a skeleton muscle into a slow-fiber-type one, which comprises ginger or a ...  

Matches 101 - 150 out of 17,015